0001193125-26-134950
SEC filingDeepening net losses and accelerated cash burn marked FY2025 as TuHURA advanced its clinical pipeline amid the Kineta acquisition, with management highlighting risks from unproven operating assumptions and ongoing negative cash flows.
TuHURA Biosciences reported a net loss of -$30.1 million for FY2025, widening 38.6% from -$21.7 million in FY2024, as the company progressed its clinical programs including the IFx-2.0 Phase 3 launch and Kineta integration. This deeper loss reflects the biotech's transitional phase, where strategic investments outpaced revenue generation typical for pre-commercial clinical-stage firms. Diluted EPS improved to -$0.63 from -$1.21—a 47.9% less negative swing—likely influenced by equity issuances that expanded the share base while funding operations.
Management's liquidity outlook emphasizes caution, noting projections rest on an operating plan with assumptions that may prove incorrect, potentially depleting capital resources sooner than anticipated. The firm anticipates ongoing net losses and negative operating cash flows for the foreseeable future, with G&A set to rise in support of R&D and any future commercialization. Investors should weigh these dynamics against TuHURA's clinical milestones, as execution risks could intensify cash burn while financing needs persist in this capital-intensive sector.